AUTHORS
Jian Huang, MD, PhD, Rumeng Li2, Sujun Gao, MD3, Hu Zhu4, Lili Chen5, Jiaping Fu6, Zonghong Shao, MD7, Xiaoming Li8, Yu Yan, MD9, Xuhan Zhang10, Zongjiu Jiao, MD11, Rong Li12, Haiping Yang, MD13, chao Li, N/A14, Lei Zhang, MD15, Wei Yang16, Jie Jin, MD17
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 Department of Hematology, The First Hospital of Jilin University, Jilin, China
4 Department of Hematology, Henan Cancer Hospital, Henan, China
5 Department of Hematology, Taizhou First People’s Hospital, Taizhou, China
6 Department of Hematology, Shaoxing People’s Hospital, SHaoping, China
7 Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China
8 Department of Hematology, The Affiliated Hospital of Southwest Medical University, Fuangzhou, China
9 Department of Hematology, The Affiliated Hospital of North China University of Science and Technology, Guangzhou, China
10 . Department of Hematology, Anhui Provincial Hospital, Hefei, China
11 Department of Hematology, Xingtai People’s Hospital, Xingtai, China
12 Department of Hematology, Panjin Liaohe Oilfield Gemflower Hospital, Panjin, China
13 Department of Hematology, The First Affiliated Hospital of Henan University of Science and Technology, Henan, China
14 Department of Hematology, Nanyang Central Hospital, Nanyang, China
15 Department of Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking, China
16 Department of Hematology, Shengjing Hospital of China Medical University, Shengjing, China
17 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ABSTRACT
Background
Polycythemia vera (PV) is characterized by JAK/STAT pathway activation, thrombohemorrhagic events, systemic symptoms, and disease transformation. OB756 is a novel oral, selective JAK2 inhibitor targeting the JAK–STAT signaling pathway. Previous studies have preliminarily demonstrated its safety and efficacy in PV patients who are resistant or intolerant to hydroxyurea or interferon. This article reports a phase III, open-label, randomized, controlled, multicenter study evaluating the efficacy and safety of OB756 tablets versus best available therapy (BAT) in patients with hydroxyurea-resistant or -intolerant PV.
Methods
This open-label, randomized, multicenter clinical trial (ChiCTR2600124544) was designed to assess the efficacy and safety of OB756 tablets compared with BAT in subjects with hydroxyurea (HU)-resistant or -intolerant PV. Enrolled subjects all met the criteria for HU resistance/intolerance. The experimental group (OB756, recommended starting dose 16 mg twice daily) comprised 51 patients, and the control group comprised 53 patients (BAT regimens could include HU, interferon, anagrelide, lenalidomide, thalidomide, pipobroman, or no medication). The primary efficacy endpoint was the composite response of no requirement for phlebotomy/apheresis from Week 4 to Week 28, and simultaneous achievement of complete hematologic response (CHR) and ≥35% reduction in spleen volume from baseline at Week 28. Secondary endpoints included the proportion of subjects maintaining the primary endpoint at Week 40; duration of CHR (from first CHR to loss of response); duration of spleen volume reduction ≥35% (from first reduction to spleen progression). Safety evaluations covered adverse event/adverse reaction incidence and severity, and laboratory parameters from first dose to 28 days after treatment end (or until new anti-PV therapy if started earlier). JAK2 V617F allele burden was quantified by allele-specific qPCR; PV-related symptoms were assessed using the MPN-SAF TSS, with symptom response defined as a ≥50% reduction in TSS from baseline (TSS50). All endpoints were analyzed per prespecified statistical methods.
Results
In this open-label, randomized trial (N=104), OB756 significantly outperformed best available therapy (BAT) in hydroxyurea-resistant/intolerant polycythemia vera patients. At week 28, the composite response rate (no phlebotomy + complete hematologic response + ≥35% spleen reduction) was 33.3% with OB756 vs 1.9% with BAT (rate difference 31.4%, P<0.0001), and 60% of OB756 responders maintained response through week 40 vs 0% for BAT. Secondary endpoints favored OB756: HCT<45% (70.1% vs 18.9%, median duration 14.8 months), spleen reduction ≥35% (68.1% vs 2.1%, median –40.5%), JAK2-V617F allele burden decline (73.8% vs 69.2%, median –5.5% vs –2.6%), and symptom response (TSS50) at week 40 (35.3% vs 0%, P=0.0506). Safety was also better with OB756: ≥Grade 3 treatment-emergent adverse events occurred in 7.8% vs 23.1% (BAT); anemia was more common in the OB756 group (39.2%, ≥Grade 3: 3.9%) but mostly mild/moderate, with no leukemia transformation, myelofibrosis progression, or new malignancies, and one unrelated death. Overall, OB756 demonstrated superior efficacy across all key measures and a favorable safety profile, supporting its broad use in PV patients.
Conclusion
This study indicates that OB756 represents a promising new therapeutic option for PV patients who are resistant or intolerant to hydroxyurea, offering significant efficacy and a favorable safety profile.
Fund:This research was supported by the National Natural Science Foundation of China (No. 82570191) and the Zhejiang Provincial Health High-level Innovative Talent Project (2022-2026).Jian Huang, M.D., Ph.D.E-mail: househuang@zju.edu.cn;
Jie Jin, M.D., PH.D. .E-mail: jiej0503@163.com
DISCLOSURES
Jian Huang, MD, PhD: No relevant conflicts of interest to declare.